Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sarepta Therapeutics reported that AVI-7288, a therapeutic drug candidate for the Marburg virus, has demonstrated up to 100% survival in a non-human primate (NHP) study exploring the drug's effect when treatment is delayed to various time points post-infection.
Subscribe to our email newsletter
The study showed a significantly higher rate of survival among NHPs treated with AVI-7288 compared to the placebo-treated group when treatment was administered up to 96-hours post infection.
Sarepta president and chief executive officer Chris Garabedian said the results are unprecedented and demonstrate a compelling proof of concept with PMOplus chemistry platform and its ability to treat the most lethal and fast-acting viruses, without compromising efficacy of survival even after up to a four-day delay in the initiation of treatment.
"These results represent a significant advancement toward the protection of our service members and the civilian population in the event of a bioterrorist attack," Garabedian added.
A high degree of survival is observed between 83% and 100% in each of four post-exposure cohorts that received daily treatments with AVI-7288 beginning one, 24, 48, or 96hours after infection, compared to 0% survival in the placebo-treated control group.
Currently at Day 27, the study will continue to monitor the surviving non-human primates until study termination at Day 41, according to the company.